Wednesday, December 27, 2006

Barr Files ANDA for Generic Thaomid, Celgene Seeking to File Patent Lawsuit!

Celgene Corp. is seeking to file a patent infringement lawsuit against Barr Pharmaceuticals after been notified by the US FDA that Barr has filed an abbreviated new drug application (ANDA) under Para IV certification with an intention to market generic version of Thamoid tablets before expiry of O.B. listed patents. The lawsuit will entitle Celgene a 30-month injunction stay against marketing generic version of Thamoid, generically known as thalidomide.

No comments:

Post a Comment